Therefore, the strategy of upregulating LRP1, a potentially important therapeutic target of BBB breakdown-related diseases, holds the potential to be used to treat both Alzheimer’s disease and Parkinson’s disease. The gene discussed is LRP1; the disease is early-onset autosomal dominant Alzheimer disease.